- Home
- DXR vs SWZ Comparison
DXR vs SWZ Comparison
Compare DXR & SWZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DXR | SWZ |
|---|---|---|
| Founded | 1970 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.4M | 76.6M |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | DXR | SWZ |
|---|---|---|
| Price | $11.50 | $6.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | 12.1K | ★ 79.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.59% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $1,446,345.00 | N/A |
| Revenue This Year | $44,935.22 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $33.83 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.10 | $5.84 |
| 52 Week High | $14.76 | $9.43 |
Technical Indicators
Market Signals| Indicator | DXR | SWZ |
|---|---|---|
| Relative Strength Index (RSI) | 41.18 | 43.33 |
| Support Level | $11.31 | $5.88 |
| Resistance Level | $14.02 | $6.10 |
| Average True Range (ATR) | 0.34 | 0.07 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 34.35 | 30.00 |
Price Performance
Historical ComparisonAbout DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About SWZ Swiss Helvetia Fund Inc. (The)
Swiss Helvetia Fund Inc is a non-diversified, closed-end investment company. Its investment objective is to seek long-term capital appreciation through investment in equity and equity-linked securities of Swiss companies. The group invests in various sectors such as pharmaceuticals, food and beverage, industrial goods and services, banks, personal and household goods, construction and materials, biotechnology, medical equipment, chemicals, technology, financial services, insurance, Semiconductors, Information Technology, and retail.